Skip to main content
. 2021 Aug 5;19(8):e06770. doi: 10.2903/j.efsa.2021.6770

Figure 2.

Figure 2

Risk characterisation for substances that are aneugenic but not clastogenic nor causing gene mutations (for more details, refer to the full text in Section 5.3)

  • *: May also be applied as a chronic HBGV if required.